Kyowa Kirin Presents New Data on Response to Treatment in Cutaneous T-cell Lymphoma (CTCL) Patients Who Have Blood Involvement
Kyowa Kirin International PLC (Kyowa Kirin), a wholly owned subsidiary of Kyowa Kirin Co., Ltd., today announced data from a post hoc analysis of the MAVORIC trial. The analysis compared the efficacy and safety of POTELIGEO®▼ (mogamulizumab) with vorinostat by patient blood classification in adult patients with mycosis fungoides (MF) and Sézary syndrome (SS), two types of CTCL.1 The data showed that higher levels of blood tumour involvement were associated with better patient outcomes in patients treated with mogamulizumab, compared to vorinostat.1
MF and SS are subtypes of CTCL, a rare type of non-Hodgkin's lymphoma that can affect the skin, blood, lymph nodes and internal organs.2 In MAVORIC, overall investigator-assessed progression-free survival (PFS) was significantly greater for patients treated with mogamulizumab compared to vorinostat, at 7.7 months and 3.1 months, respectively (P<0.0001).1 When data were stratified by blood classification, PFS was found to be significantly greater for mogamulizumab compared to vorinostat in patients with higher levels of blood involvement, known as B1 and B2 blood classifications.1
Professor Julia Scarisbrick, Consultant Dermatologist, lead author of this analysis from the study said: “In MF and SS, assessing the stage of the disease is key to prognosis, appropriate treatment and patient outcome. Assessment of blood involvement is part of this staging process. The data highlights that mogamulizumab is more effective in MF and SS patients who have blood involvement as part of their disease. Blood involvement is relatively common in the more advanced stages of CTCL and may be present in as many as 20% of less advanced cases.3 This new information could help improve the clinical management of MF and SS patients and highlights the need for blood monitoring.”
Overall response rate (ORR) was also significantly greater for mogamulizumab than vorinostat in the MAVORIC trial at 28% and 5% respectively (P<0.0001).1 In this analysis, ORR was also found to be significantly greater for mogamulizumab than vorinostat in patients with B2 blood classification.1 Difference in ORR for patients with B1 blood classification was not significant between the two treatment groups.1 Difference in time-to-next-treatment (TTNT) was not significant for patients without blood involvement (B0 classification), but was significantly greater for mogamulizumab in patients with B1 or B2 blood involvement, 13.70 vs 3.30 months for mogamulizumab and vorinostat, respectively (P<0.0001).1 Drug-related treatment-emergent adverse events (TEAEs) were similar in patients regardless of blood involvement and were lower for mogamulizumab than vorinostat at each blood classification level.1
Danie du Plessis, Executive Vice President, Medical Affairs (EMEA) at Kyowa Kirin, commented: “We welcome the results of this analysis in furthering our understanding of the role of mogamulizumab in treating MF and SS patients. Research suggests that patients with B1 and B2 blood classifications may have reductions in median survival and an increased risk of disease progression, compared to those classified as B0.4 Through our work with this therapy, we are aiming to address the unmet needs in these patient populations and are dedicated to improving outcomes for people with MF and SS.”
The data will be presented today in a poster session at the 16th European Association of Dermato Oncology (EADO) Congress.1
About Mycosis Fungoides (MF) and Sézary syndrome (SS)
MF and SS are subtypes of cutaneous T-cell lymphoma (CTCL), a rare type of non-Hodgkin's lymphoma that can affect the skin, blood, lymph nodes and internal organs.2 CTCL is rare. For every 100,000 people in Europe, there are approximately 24 cases of CTCL.5 Together they represent approximately 65% of all cases of CTCL.2 Individuals with this disease often suffer from disfiguring, itchy, painful and unpredictable skin symptoms, which can lead to further complications that can impact their life expectancy.6,7
MF and SS are characterised by localisation of cancerous white blood cells called T lymphocytes (T cells), to the skin.8,9 These cancerous T cells consistently express a protein called CC-chemokine receptor 4 (CCR4), which enables them to move from the blood to the skin.10,11,12 When these cancerous T cells move to the skin, they can create a localised inflammatory immune skin response, commonly resulting in visible skin symptoms of red patches or plaques, 10,13,14,15,16 which can resemble psoriasis or eczema.8
MF and SS can affect the skin, blood, lymph nodes (part of the body’s immune system which is spread throughout the body) and internal organs.2 All four areas of the body are used to assess disease stage17,18 and clinically significant involvement of the blood, particularly in more advanced disease, is linked with increased morbidity and an overall reduction in patient survival.17,19,20
Due to its likeness to more common skin conditions such as eczema and psoriasis,8 CTCL can take, on average, between 2 and 7 years for individuals to receive a confirmed diagnosis.21 It is critical for doctors to diagnose CTCL as early as possible as the patient’s prognosis can be affected if the disease progresses to later stages.4 Whilst most individuals that present with early stage do not progress to a more advanced stage,22 patients with advanced disease have significantly poorer outcomes with only around half of patients (52%) surviving for just 5 years.17
POTELIGEO is a first-in-class humanised monoclonal antibody (mAb), designed to bind to CC chemokine receptor 4 (CCR4).7 After POTELIGEO binds to CCR4, it increases affinity of immune cells from the immune system to target the cancerous cells.23 POTELIGEO uses Kyowa Kirin’s proprietary POTELLIGENT® technology.23
Following a positive opinion from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), the European Commission (EC) granted marketing authorisation for POTELIGEO in November 2018 for the treatment of adult patients with MF or SS who have received at least one prior systemic therapy.24 The CHMP’s opinion was based on results of the MAVORIC trial, the largest randomised study of systemic therapy in MF and SS,7 and the first trial to compare systemic therapies using progression-free survival as a primary endpoint.7
About the MAVORIC Trial
- The MAVORIC trial is the largest randomised study of systemic therapy conducted in MF and SS,7 and the first trial to compare systemic therapies using ‘progression-free survival’ (PFS) as a primary endpoint, which incorporates looking at disease progression in four different compartments of the body (skin, blood, lymph nodes and internal organs).7
- Secondary endpoints were overall response rate; duration of response (time from first achievement of an overall response to progression or death); the proportion of patients with an overall response in the crossover portion of the trial; assessment of quality of life; immunogenicity (immune response) and safety.7
Results showed that:
- In patients taking POTELIGEO disease was controlled for more than twice as long as in those taking the comparator treatment, vorinostat* (PFS of 7.7 mths vs 3.1 mths) (HR=0.53, 95% CI: 0.41–0.69; p<0.0001).7
- Overall significantly more patients responded to POTELIGEO than vorinostat* (Overall Response Rate [ORR] 28% versus 5%; Risk Ratio [RR]: 23.1; 95% CI 12.8–33.1, P<0.0001).7
- Response to treatment lasted 43% longer in people taking POTELIGEO versus those taking vorinostat* (14.1 months versus 9.1 months).7
- More patients responded to POTELIGEO, across all studied MF/SS disease stages than with vorinostat.* 7
- POTELIGEO has overall good tolerability with a manageable safety profile.7,25
- The most common adverse reactions with POTELIGEO are constipation, diarrhoea, nausea, stomatitis, fatigue, oedema (peripheral), pyrexia, infections, infusion related reactions, headache and drug eruption (including skin rash).24
*Vorinostat is a USA FDA-licensed existing treatment for MF and SS and is currently unlicensed in the EU
Important Safety Information
Refer to the full Summary of Product Characteristics (SmPC) for full safety information: https://www.ema.europa.eu/en/medicines/human/EPAR/poteligeo#product-information-section
About Kyowa Kirin
Kyowa Kirin commits to innovative drug discovery driven by state-of-the-art technologies. The company focuses on creating new values in the four therapeutic areas: nephrology, oncology, immunology/allergy and neurology. Under the Kyowa Kirin brand, the employees from 40 group companies across North America, EMEA, and Asia/Oceania unite to champion the interests of patients and their caregivers in discovering solutions wherever there are unmet medical needs.
You can learn more about Kyowa Kirin at: https://www.kyowakirin.com/
1 Scarisbrick J, et al. Efficacy and Safety of Mogamulizumab by Patient Blood Classification. Abstract from 16 European Association of Dermato Oncology Congress. 2020;1-4.
2 Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-22.
3 Scarisbrick JJ, Quaglino P, Prince HM, et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol. 2019;181:350–357.
4 Agar N, et al. Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sezary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal. J Clin Ocol. 2010;28(31):4730-4739.
5 Orphanet: Prevalence and incidence of rare diseases: Bibliographic data. Available from: https://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_decreasing_prevalence_or_cases.pdf. Last accessed: September 2020.
6 Haun P, et al. Fast Facts: Diagnosing Cutaneous T-Cell Lymphoma. Karger Publishing. 2016.
7 Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192-1204.
8 Cutaneous Lymphoma Foundation, Lymphoma Action and Lymphoma Coalition Europe. Cutaneous lymphoma – a patient’s guide. 2019. Available from: https://lymphoma-action.org.uk/sites/default/files/media/documents/2019-06/Cutaneous%20lymphoma%20-%20patient%26%23039%3Bs%20guide%20-%20English%20language%20source%20document%20-%20final%20version%20for%20publication%20-%20April%202019.pdf. Last accessed: September 2020.
9 Mariani M, Lang R, Binda E, et al. Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 cells. Eur J Immunol. 2004;34(1):231-240.
10 Ferenczi K, Fuhlbrigge RC, Pinkus J, et al. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol. 2002;119:1405-10.
11 Yoshie O, et al. Frequent Expression of CCR4 in Adult T-Cell Leukemia and Human T-cell Leukemia Virus Type 1-transformed T cells. Blood. 2002;99(5):1505-11.
12 Ishida T, et al. Clinical Significance of CCR4 Expression in Adult T-cell Leukemia/Lymphoma: Its Close Association With Skin Involvement and Unfavorable Outcome. Clin Cancer Res. 2003;9:3625-34.
13 Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(1):151-65.
14 Ni X, Jorgensen JL, Goswami M, et al. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome. Clin Cancer Res. 2014;21(2):274-85.
15 Kakinuma T, Sugaya M, Nakamura K, et al. Hymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol. 2003;48(1):23-30.
16 Girardi M, Heald PW, Wilson LD. The Pathogenesis of Mycosis Fungoides. NEJM. 2004;350(19):1978-88.
17 Scarisbrick JJ, Prince M, Vermeer MH, et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol. 2015;33(32):3766-3773.
18 Willemze R, Hodak E, Zinzani PL et al. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(4):1-29.
19 Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115(4):798-812.
20 Scarisbrick JJ, Whittaker, S, Evans, AV, et al. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood. 2001;97(3):624-30.
21 CL Foundation: A Patient’s Guide. Available from: https://www.clfoundation.org/sites/default/files/2018-04/a_patients_guide.pdf. Last Accessed: September 2020
22 Krejsgaard T, Lindahl LM, Mongan NP, et al. Malignant inflammation in cutaneous T-cell lymphoma—a hostile takeover. Semin Immunopathol. 2017;39(3):269–282.
23 Duvic M, et al. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016;7(3):171-174.
24 POTELIGEO SMPC. Available from: https://www.ema.europa.eu/en/documents/product-information/poteligeo-epar-product-information_en.pdf Last accessed: September 2020.
25 Kim YH, Bagot M, Zinzani PL et al. Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study. Blood. 2019;134 (1):5300.
Contacts for Kyowa Kirin International:
+44 (0) 7769 656073
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ADVA posts quarterly revenues of EUR 146.7 million for Q3 202022.10.2020 01:55:00 EEST | Press release
ADVA (ISIN: DE0005103006), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported final financial results for Q3 2020 ended on September 30, 2020. The results have been prepared in accordance with International Financial Reporting Standards (IFRS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201021006074/en/ Uli Dopfer, CFO, ADVA (Photo: Business Wire) Q3 2020 financial summary1 (in thousands of EUR) Q3 Q3 Change Q2 Change 2020 2019 2020 Revenues 146,676 144,310 1.6% 145,024 1.1% Pro forma gross profit 51,930 49,086 5.8% 50,204 3.4% in % of revenues 35.4% 34.0% 1.4pp 34.6% 0.8pp Pro forma operating income 11,053 7,393 49.5% 10,107 9.4% in % of revenues 7.5% 5.1% 2.4pp 7.0% 0.5pp Operating income2 9,768 3,200 205.3% 8,658 12.8% Net income2 6,671 2,190 204.6% 7,629 -12.6% (in thousands of EUR) Sep. 30 2020 Sep. 30 2019 Change Jun. 30 2020 Change Cash and cash equivalents 68,2
ADVA Optical Networking SE announces Q3 2020 financial results and releases new guidance for full year 202022.10.2020 01:30:00 EEST | Press release
Revenues in the third quarter of 2020 were EUR 146.7 million, up 1.6% from the year-ago quarter (Q3 2019: EUR 144.3 million). The pro forma operating income increased by 49.5% to EUR 11.1 million (Q3 2019: EUR 7.4 million) amounting to 7.5% of revenues compared to 5.1% in the year-ago quarter. Based on the financial results for the third quarter and the current assumptions about business development in the fourth quarter of 2020, the management board of ADVA Optical Networking SE (ISIN: DE0005103006 FSE: ADV) today released new guidance for the 2020 financial year. The management board now expects revenues between EUR 565 million and EUR 580 million and a pro forma operating income between 5% and 6% as a percentage of revenues for the full year 2020. For the remainder of 2020 financial year, the further course of the global infection rates and associated further possible lockdown scenarios will be decisive. The new forecast assumes that the consequences of the Covid-19 pandemic will no
Bentley Systems Announces Winners of Year in Infrastructure 2020 Awards21.10.2020 21:30:00 EEST | Press release
Bentley Systems, Incorporated, (Nasdaq: BSY), the infrastructure engineering software company, has announced the winners of the Year in Infrastructure 2020 Awards. The annual awards program honors the extraordinary work of Bentley users advancing design, construction, and operations of infrastructure throughout the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201021005893/en/ All Year in Infrastructure 2020 Award winners, finalists, and nominees will be featured in the 2020 Infrastructure Yearbook, which will be published in early 2021. (Photo: Business Wire) Sixteen independent jury panels selected the 57 finalists from over 400 nominations submitted by more than 330 organizations from more than 60 countries. Bentley Systems acknowledged 19 Year in Infrastructure 2020 Awards winners and 14 Special Recognition awardees on October 21 during the Year in Infrastructure 2020 Conference, held virtually for the first time
Saudi Arabia Sets out Strategy to Become a World Leader in Artificial Intelligence By 203021.10.2020 19:07:00 EEST | Press release
Saudi Arabia revealed its National Strategy for Data & AI (NSDAI) which will make the country a global leader in Artificial Intelligence by 2030. Saudi Arabia’s NSDAI intends to put AI at the heart of the country’s development and growth. By 2030, Saudi Arabia’s vision is to become the place where the best of Data and AI is made reality. Under the strategy, Saudi Arabia will implement a multi-phase, multi-faceted plan that includes skills, policy and regulation, investment, research and innovation, and ecosystem development. This will enable the country to become a global hub for data and AI, and to rank among the top data-driven economies in the world. Speaking at the launch of the strategy, HE Dr. Abdullah Bin Sharaf Alghamdi, President of SDAIA, said: “The National Strategy for Data and AI sets the direction and foundations upon which we will unlock the potential of data and AI to fulfill our national transformation priorities and establish Saudi Arabia as a global hub for data and
Women 20 (W20) Challenges G20 Leaders to Close the Gap Between Imagination and Reality on Women’s Equality21.10.2020 19:01:00 EEST | Press release
Women 20 (W20), the women’s engagement group to the G20, challenged G20 leaders to live up to their promises of the past and make women’s economic equality a reality. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201021005766/en/ W20 Chair Dr. Thoraya Al Obaid and G20 Chair of Trade and Investment His Excellency Dr. Majid Alqassabi with the final Communiqué of the W20 Working Group (Photo: AETOSWire) Laying out measures to expedite the economic recovery from the COVID-19 pandemic, the W20 presented its Communiqué to H.E. Dr. Majid Alqassabi, Minister of Commerce, Chair of G20 Trade and Investment, representing the Presidency of the G20. The pandemic provides an opportunity for G20 leaders to reset G20 economies based on the full and equitable participation of women. “Unless urgent action is taken, the pandemic will continue to exacerbate gender inequalities, expose vulnerabilities, and roll back gains made on women’s equali
Saudi Arabia Partners With the World Bank to Ensure No Nation Is Left Behind on AI21.10.2020 18:59:00 EEST | Press release
The World Bank and Saudi Arabia have announced a long-term partnership to accelerate the use of Artificial Intelligence (AI) in developing nations in support of economic and development goals. The objective is to ensure that no nation is left behind in the race to unlock the value of AI while ensuring the appropriate safeguards are in place to manage the risks associated with AI. Under the partnership, the World Bank and Saudi Arabia, represented by the Saudi Data and Artificial Intelligence Authority (SDAIA), will cooperate to assist countries in creating policies and initiatives that harness the power of AI to support national development and growth. AI and related technologies are expected to unlock an additional $15tn of economic value worldwide before 2030, but many developing nations do not have yet the technical readiness to share in this new wealth. The partnership will support target nations to identify gaps in their own readiness and ability to utilize AI and data and develop
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom